Nicholas Investment Partners LP Sells 45,655 Shares of Harrow, Inc. (NASDAQ:HROW)

Nicholas Investment Partners LP reduced its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 65.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,822 shares of the company's stock after selling 45,655 shares during the period. Nicholas Investment Partners LP owned 0.07% of Harrow worth $799,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its stake in shares of Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Harrow during the fourth quarter worth $78,000. AlphaQuest LLC boosted its holdings in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after purchasing an additional 2,889 shares during the period. Federated Hermes Inc. acquired a new position in shares of Harrow in the 4th quarter valued at about $214,000. Finally, Maridea Wealth Management LLC bought a new stake in shares of Harrow during the 4th quarter valued at about $222,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Performance

HROW stock traded down $0.38 on Tuesday, reaching $27.92. 52,345 shares of the company were exchanged, compared to its average volume of 495,605. The firm has a market capitalization of $1.02 billion, a PE ratio of -29.62 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 12 month low of $15.97 and a 12 month high of $59.23. The stock's fifty day moving average price is $25.14 and its 200 day moving average price is $31.69.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The firm had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. On average, research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HROW shares. HC Wainwright boosted their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. B. Riley decreased their price target on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.